- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 11.09. | Zenas BioPharma, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 09.09. | Zenas BioPharma auf Citi-Konferenz: Pipeline-Strategie und Finanzplanung vorgestellt | 3 | Investing.com Deutsch | ||
| 08.09. | Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event | 1 | GlobeNewswire (USA) | ||
| 18.08. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 3 | GlobeNewswire (USA) | ||
| 13.08. | Zenas BioPharma GAAP EPS of -$1.77 misses by $0.65, revenue of $1M | 2 | Seeking Alpha | ||
| ZENAS BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 13.08. | Zenas BioPharma, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.08. | Zenas BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.07. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 17.06. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 11.06. | Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit | 1 | GlobeNewswire (USA) | ||
| 03.06. | H.C. Wainwright bestätigt Kaufempfehlung für Zenas Biopharma nach Studienerfolg | 3 | Investing.com Deutsch | ||
| 03.06. | H.C. Wainwright reiterates Zenas Biopharma stock rating at buy | 1 | Investing.com | ||
| 03.06. | Zenas BioPharma reports positive phase 3 trial results for obexelimab | 2 | Investing.com | ||
| 03.06. | Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine | 2 | GlobeNewswire (USA) | ||
| 28.05. | Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | 609 | GlobeNewswire (Europe) | - BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (Nasdaq:... ► Artikel lesen | |
| 19.05. | Zenas BioPharma präsentiert Studiendaten zu Obexelimab auf dem EULAR-Kongress | 1 | Investing.com Deutsch | ||
| 19.05. | Zenas BioPharma to present obexelimab trial data at EULAR congress | 3 | Investing.com | ||
| 19.05. | Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress | 365 | GlobeNewswire (Europe) | - Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at 2:45 PM GMT - WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 18.05. | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AMGEN | 342,35 | +1,98 % | Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the FDA approved an update to the IMDELLTRA Prescribing Information that substantially reduces the recommended monitoring time for the first... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 689,60 | +0,53 % | Regeneron auf Morgan Stanley Konferenz: Wachstum stützt sich auf Dupixent | ||
| VIKING THERAPEUTICS | 25,100 | -0,59 % | Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. | ||
| TEMPUS AI | 68,57 | +1,20 % | Goldman Sachs startet Coverage für Tempus AI Aktie mit "Neutral"-Rating | ||
| BIOMARIN PHARMACEUTICAL | 55,92 | +0,47 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors | SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D.... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 59,18 | +2,18 % | Arrowhead Pharmaceuticals bei H.C. Wainwright: Markteinführung und breite Pipeline im Fokus | ||
| INSMED | 107,22 | +2,62 % | Insmed Incorporated: FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 | -sNDA Under Review for Full Approval Is Based on Positive Results From Phase 3b ENCORE Study-
-Full Approval Could Bring ARIKAYCE to Patients Earlier in Their... ► Artikel lesen | |
| SWEDISH ORPHAN BIOVITRUM | 39,560 | +0,05 % | Innate Pharma SA: Innate and Sobi Announce Partnership Is Now Effective Following Completion of Closing Conditions | The partnership between Sobi and Innate is now effective, following expiration of the anti-trust waiting periods and completion of other conditions Transaction closing triggers the USD... ► Artikel lesen | |
| SCHOLAR ROCK | 41,200 | +1,50 % | JPMorgan raises Scholar Rock stock price target to $70 on launch outlook | ||
| PROQR THERAPEUTICS | 1,650 | +3,25 % | ProQR Therapeutics N.V.: ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026 | LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative... ► Artikel lesen | |
| ENSYSCE BIOSCIENCES | 0,428 | -6,22 % | Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation | SAN DIEGO, CA / ACCESS Newswire / September 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 78,65 | +1,86 % | Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why | ||
| TEVOGEN | 6,470 | +1,65 % | XFRA G280: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| QIAGEN | 38,695 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,280 | +2,54 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen |
ZENAS BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 32,530 Euro und damit +3,27 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZENAS BIOPHARMA INC finden Sie auf Wallstreet Online.